The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Role of gemcitabine in cancer therapy
Abstract
Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new cytotoxic agents. The drug has shown activity in a variety of solid tumors, and has been approved for the treatment of non-small cell lung cancer, pancreatic, bladder, and breast cancer. Recent data showed that gemcitabine is also active against ovarian cancer. Gemcitabine has a good toxicity profile, with myelosuppression being the most common side effect, while non-hematological events are relatively uncommon. The low toxicity profile makes the drug a valid option for unfit and elderly patients. Due to the synergistic activity with other chemotherapeutic compounds, mainly cisplatinum, several trials have been conducted to evaluate the efficacy and tolerability of gemcitabine in combination with other cytotoxic agents. Current clinical trials are evaluating the role of gemcitabine in combination with new targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., Barbera, S., Ferrau, F., Piazza, E., Rosetti, F., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.362 · Cited by 781
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712
Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Herr, H. W., Morse, M. J., Sogani, P. C., Vaughan, E. D., Bander, N., Weiselberg, L. R., et al. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42494-3 · Cited by 627
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Tempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., & Abbruzzese, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.140 · Cited by 519
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
Cardenal, F., López-Cabrerizo, M. P., Antón, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., García, M., Lianes, P., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.12 · Cited by 471
Frasci, G., Lorusso, V., Panza, N., Comella, P., Nicolella, G., Bianco, A., De Cataldis, G., Iannelli, A., Bilancia, D., Belli, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2529 · Cited by 447
Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., Buckels, J. A. C., & for the Marimastat Pancreatic Cancer Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3447 · Cited by 438
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 396
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · PubMed · Cited by 384
Crinò, L., Scagliotti, G. V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3522 · Cited by 362
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1535 · Cited by 359
Rosell, R., Danenberg, K. D., Alberola, V., Bepler, G., Sanchez, J. J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0156 · Cited by 352
Smit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351
Georgoulias, V, Papadakis, E., Alexopoulos, A., Tsiafaki, X., Rapti, A., Veslemes, M., Palamidas, P., & Vlachonikolis, I. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04644-4 · Cited by 346
Anderson, H., Hopwood, P., Stephens, R. J., Thatcher, N., Cottier, B., Nicholson, M., Milroy, R., Maughan, T. S., Falk, S. J., Bond, M. G., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1307 · Cited by 338
Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael, J., Possinger, K., Phillip, P., Beykirch, M., Kerr, H., Walling, J., & Harris, A. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2731 · Cited by 338
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7010 · Cited by 312
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · Cancer · doi:10.1002/cncr.10323 · Cited by 307
Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Peters, G. J. (1996) · PubMed · Cited by 304
Lorusso, V, Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., & De Lena, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00030-6 · Cited by 286
Davidson, J. D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L. M., & Slapak, C. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3363 · Cited by 280
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Kaufman, D., Raghavan, D., Carducci, M., Levine, E. G., Murphy, B., Aisner, J., Kuzel, T., Nicol, S., Oh, W., & Stadler, W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1921 · Cited by 257
Kosmidis, P., Mylonakis, N., Nicolaides, C., Kalophonos, C., Samantas, E., Boukovinas, J., Fountzilas, G., Skarlos, D., Economopoulos, T., Tsavdaridis, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.112 · Cited by 255
Gatzemeier, U., Shepherd, F. A., Le Chevalier, T., Weynants, P., Cottier, B., Groen, H. J. M., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00444-0 · Cited by 241
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep, J. R., Loves, W. J. P., van der Wilt, C. L., Álvarez, E., Talianidis, I., Boven, E., Braakhuis, B. J. M., van Groeningen, C. J., Pinedo, H. M., & Peters, G. J. (2002) · PubMed · Cited by 224
Moorsel, C. J. A. V., Pinedo, H. M., Veerman, G., Bergman, A. M., Kuiper, C. M., Vermorken, J. B., van der Vijgh, W. J. F., & Peters, G. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690452 · Cited by 192
Abratt, R. P., Bezwoda, W. R., Goedhals, L., & Hacking, D. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.744 · Cited by 177
A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy
Fung, M. C., Storniolo, A. M., Nguyen, B., Arning, M., Brookfield, W., & Vigil, J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c2023::aid-cncr21%3e3.0.co;2-2 · Cited by 164
Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial
Blackstein, M., Vogel, C. L., Ambinder, R., Cowan, J., Iglesias, J., & Melemed, A. (2002) · Oncology · doi:10.1159/000048240 · Cited by 161
Achiwa, H., Oguri, T., Sato, S., 前田, 浩., Niimi, T., & Ueda, R. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03257.x · Cited by 157
Perng, R. P., Chen, Y. M., Liu, J. M., Tsai, C.-M., Lin, W., Yang, K., & Whang‐Peng, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2097 · Cited by 148
Possinger, K., Kaufmann, M., Coleman, R., Stuart, N., Helsing, M., Ohnmacht, U., & Arning, M. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199902000-00003 · Cited by 130
Rosell, R., Felip, E., Tarón, M., Majo, J., Méndez, P., Sanchez-Ronco, M., Queralt, C., Sánchez, J. J., & Maestre, J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040006 · Cited by 128
Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.
Fa, S., Abratt, R. P., Anderson, H., et al. (1997) · PubMed · Cited by 100
Nagourney, R. A., Brewer, C. A., Radecki, S. E., Kidder, W. A., Sommers, B. L., Evans, S. S., Minor, D. R., & DiSaia, P. J. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6855 · Cited by 91
Rothenberg, M. L., Sharma, A. B., Weiss, G. R., Villalona-Calero, M. A., Eckardt, J. R., Aylesworth, C., Kraynak, M. A., Rinaldi, D. A., Rodriguez, G., Burris, H. A., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008286908930 · Cited by 75
van Haperen, V. W. T. R., Veerman, G., Vermorken, J. B., Pinedo, H. M., & Peters, G. J. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02402-6 · Cited by 75
Gridelli, C., Frontini, L., Perrone, F., Gallo, C., Gulisano, M., Cigolari, S., Castiglione, F., Robbiati, S. F., Gasparini, G., Ianniello, G. P., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1341 · Cited by 60
Edelman, M. J., Clark, J. I., Chansky, K., Albain, K. S., Bhoopalam, N., Weiss, G. R., Giguere, J. K., Kelly, K. L., Crowley, J. J., & Gandara, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0002 · Cited by 56
Rinaldi, M., Crinò, L., Scagliotti, G. V., Mosconi, A. M., de Marinis, F., Gridelli, C., Selvaggi, G., Giulia, M. D., Darwish, S., Porrozzi, S., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008334610955 · Cited by 55
Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
Beretta, G. D., Michetti, G., Belometti, M. O., Gritti, G., Quadri, A., Poletti, P. L., & Labianca, R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1304 · Cited by 49
Isokangas, O.-P., Knuuttila, A., Halme, M. K., Mäntylä, M., Lindström, I., Nikkanen, V., Virén, M., Joensuu, H., & Mattson, K. V. (1999) · Annals of Oncology · doi:10.1023/a:1008305017829 · Cited by 41
van Moorsel, C. J. A., Pinedo, H. M., Veerman, G., Guechev, A., Smid, K., Loves, W. J. P., Vermorken, J. B., Postmus, P. E., & Peters, G. J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00316-5 · Cited by 37
Edelman, M. J. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.s.002 · Cited by 12
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.
Herbst, R. S., & Lilenbaum, R. (1999) · PubMed · Cited by 12
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., et al. (2007) · Nature · doi:10.1038/nature05697 · Cited by 474
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, A. K., & Halbrook, C. J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2022 · Cited by 150
Metadata
- Authors
- Toschi, L., Finocchiaro, G., Bartolini, S., Gioia, V, & Cappuzzo, F.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2005-02
- Volume
- 1
- Issue
- 1
- Pages
- 7-17
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2098158472
- Cited by
- 373
- References
- 56
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.